GSK – GlaxoSmithKline plc

GSK plc

GSK

$46.55

Name : GSK plc

Sector : Healthcare

Industry: Drug Manufacturers - General

Mark. Cap: $93,263,634,432.00

EPSttm : 3.17

GSK plc

$46.55

1.02%

$0.48

GSK — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.73

Margin Of Safety %

Put/Call OI Ratio

0.67

EPS Next Q Diff

-0.57

EPS Last/This Y

1.06

EPS This/Next Y

0.22

Price

46.53

Target Price

58.33

Analyst Recom

2.57

Performance Q

-12.74

Upside

-11.4%

Beta

0.3

Ticker: GSK

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-08	GSK	48.57	0.61	0.85	55230
2026-09-09	GSK	48.64	0.65	1.07	57228
2026-09-10	GSK	48.13	0.65	1.27	57438
2026-09-11	GSK	48.13	0.66	0.86	57827
2026-09-14	GSK	50.04	0.67	0.18	56597
2026-09-15	GSK	50	0.65	0.63	57427
2026-09-16	GSK	50.31	0.65	0.54	57754
2026-09-17	GSK	51.06	0.65	3.49	58290
2026-09-18	GSK	50.2	0.70	0.37	60509
2026-09-21	GSK	51.09	0.75	0.20	52799
2026-09-22	GSK	50.73	0.72	0.47	54922
2026-09-23	GSK	49.72	0.72	0.69	55352
2026-09-24	GSK	49.65	0.72	0.56	56013
2026-09-25	GSK	49.24	0.72	1.05	56907
2026-09-28	GSK	49.7	0.68	0.23	53191
2026-09-29	GSK	49.36	0.66	0.13	54212
2026-09-30	GSK	48.19	0.66	0.25	54415
2026-10-01	GSK	47.18	0.66	0.54	55197
2026-10-02	GSK	47.03	0.65	0.31	55406
2026-10-05	GSK	46.53	0.67	0.22	53623
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-08	GSK	48.57	-7.2	3993.5	4.79
2026-09-09	GSK	48.62	-7.2	4645.6	4.79
2026-09-10	GSK	48.13	-7.2	4268.1	4.79
2026-09-11	GSK	48.12	-7.2	4581.7	4.79
2026-09-14	GSK	50.05	-7.2	4891.4	4.79
2026-09-15	GSK	49.99	-7.2	4358.8	4.79
2026-09-16	GSK	49.99	-7.2	4358.8	4.79
2026-09-17	GSK	51.06	-7.2	4529.5	4.79
2026-09-18	GSK	50.21	-7.2	4141.2	4.79
2026-09-21	GSK	51.09	-7.2	4392.1	4.79
2026-09-22	GSK	50.74	-7.2	4148.1	4.79
2026-09-23	GSK	49.73	-7.2	3959.3	4.79
2026-09-24	GSK	49.64	-7.2	4053.6	4.79
2026-09-25	GSK	49.23	-7.2	4016.1	4.78
2026-09-28	GSK	49.70	-7.2	4391.2	4.80
2026-09-29	GSK	49.36	-7.2	4197.1	4.80
2026-09-30	GSK	48.19	-7.2	4011.7	4.80
2026-10-01	GSK	47.18	-7.2	4080.8	4.80
2026-10-02	GSK	47.03	-7.2	4289.3	4.80
2026-10-05	GSK	46.53	-7.2	4365.7	4.80
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-08	GSK	0.00	-2.67	0.74
2026-09-09	GSK	0.00	-2.67	0.74
2026-09-10	GSK	0.00	-2.67	0.74
2026-09-11	GSK	0.00	-2.67	0.68
2026-09-14	GSK	0.00	-2.37	0.68
2026-09-15	GSK	0.00	-2.37	0.68
2026-09-16	GSK	0.00	-2.37	0.68
2026-09-17	GSK	0.00	-2.37	0.68
2026-09-18	GSK	0.00	-2.37	0.68
2026-09-21	GSK	0.00	-2.32	0.68
2026-09-23	GSK	0.00	-2.32	0.68
2026-09-24	GSK	0.00	-2.32	0.68
2026-09-25	GSK	0.00	-2.32	0.73
2026-09-28	GSK	0.00	-2.45	0.73
2026-09-29	GSK	0.00	-2.45	0.73
2026-09-30	GSK	0.00	-2.45	0.73
2026-10-01	GSK	0.00	-2.45	0.73
2026-10-02	GSK	0.00	-2.45	0.73
2026-10-05	GSK	0.00	-2.01	0.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

1.36

Avg. EPS Est. Current Quarter

1.35

Avg. EPS Est. Next Quarter

0.79

Insider Transactions

Institutional Transactions

-2.01

Beta

0.3

Average Sales Estimate Current Quarter

11789

Average Sales Estimate Next Quarter

11865

Fair Value

65.35

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

24.6

Max Drawdown 5-Year %

-39.3

Target Price

58.33

P/E

14.66

Forward P/E

9.14

PEG

1.98

P/S

2.09

P/B

4.02

P/Free Cash Flow

10.69

EPS

3.17

Average EPS Est. Cur. Y

4.8

EPS Next Y. (Est.)

5.02

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

14.56

Relative Volume

0.94

Return on Equity vs Sector %

1.2

Return on Equity vs Industry %

-8.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

4365.7

◆ GSK Healthcare

$46.53

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

15/25

Volume

7/15

Valuation

18/20

TP/AR

0/10

Options

6/10

RSI

31.8

Range 1M

8.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

17/25

Growth

5/30

Estimates

6/20

Inst/Vol

2/15

Options

8/10

EPS Yr

1.8%

EPS NY

6.4%

52W%

20.6%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +37.3% upside

Quality

25/30

Valuation

15/30

Growth

7/25

Stability

3/10

LT Trend

4/5

Upside

+37.3%

Quality

MoS

40%

GSK — P/E HistoricalDrug Manufacturers - General

GSK plc

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 66841

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

GSK

Latest News

—

Caricamento notizie per GSK…

stock quote shares GSK – GlaxoSmithKline plc Stock Price stock today

news today GSK – GlaxoSmithKline plc stock forecast ,stock prediction 2023 2024 2025

marketwatch GSK – GlaxoSmithKline plc yahoo finance google finance

stock history GSK – GlaxoSmithKline plc invest stock market

stock prices GSK premarket after hours

ticker GSK fair value insiders trading

GSK – GlaxoSmithKline plc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GSK

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y